Guest guest Posted November 12, 2004 Report Share Posted November 12, 2004 Dang. Nobody threw their hat in the ring for Mycotic Diseases? OTOH, why study disorders that are not acknowledged to exist? --- In , " tigerpaw2c " <tigerpaw2C@n...> wrote: > > CDC Announces $5 Million in New Awards to Fight Emerging Infectious > Diseases > > 11/10/2004 3:12:00 PM > > http://releases.usnewswire.com/GetRelease.asp?id=39623 > --------------------------------------------------------------------- > ----------- > > State Desk, Health Reporter > > Contact: Morcone of the Centers for Disease Control and > Prevention, 404-639-1690 > > ATLANTA, Nov. 10 /U.S. Newswire/ -- The Centers for Disease Control > and Prevention today announced $5 million in new grants to support > infectious disease research in five major areas including influenza > vaccine effectiveness, antimicrobial resistance, Clostridium > difficile-associated diarrheal disease, West Nile virus infection, > and organ transplant-associated infections. > > " The primary objective of CDC's peer-reviewed research grants is to > support high quality studies whose findings can be applied by public > health practitioners and policy makers to improve health, " said Dr. > M. , director of CDC's National Center for Infectious > Diseases. " Each study aims to address an important public health > concern with substantial potential disease impact. " > > Listed below are brief descriptions of the studies, along with the > names of the principal investigators and their institutions. > > Annual influenza vaccine effectiveness: > > A. Belongia, M.D., Marshfield Clinic Research Foundation, > Marshfield, Wisconsin. This project aims to provide a rapid analysis > of influenza vaccine effectiveness throughout influenza season to > better understand how vaccination protects those who receive > vaccine. > > Applied research on antimicrobial resistance: > > Engemann, M.D., Duke University, Durham, North Carolina. The > investigators will study the impact of methicillin-resistant > Staphylococcus aureus on length of hospitalization and cost of > treatment. > > Ruth Lynfield, M.D., Minnesota Department of Health, Minneapolis, > Minnesota. This work will determine the economic costs of > methicillin-resistant S. aureus infections. > > J. Fraser, M.D., Washington University, St. Louis, > Missouri. This research will measure the economic costs of > infections caused by several antibiotic-resistant pathogens in a > hospital setting. > > R. , M.D., University of Minnesota, Minneapolis, > Minnesota. This study will address the transmission of antibiotic- > resistant E. coli organisms from poultry to humans. > > E. Wittum, Ph.D., Ohio State University Research Foundation, > Columbus, Ohio. The goal of this research is to assess the public > health risk of the antibiotic drug ceftiofur's use in food chain > animals. > > Prevention epicenters: Studies within this program are designed to > develop, implement, and evaluate the effectiveness of > epidemiologically-based strategies to improve healthcare quality and > ensure patient safety by preventing healthcare-associated infections > and reducing antimicrobial resistance. > > Fraser, M.D., Washington University, St. Louis, Missouri. > This research will examine the effect of antimicrobial agents on the > incidence of Clostridium difficile associated diahrrheal disease, > its impact on the cost of healthcare, and the influence that the use > of different disinfection agents have on its incidence. > > Loreen Herwaldt, M.D., University of Iowa, Iowa City, Iowa. This > group will analyze errors that resulted in incorrect identification > of infectious disease agents from blood cultures from laboratories > in several states in order to develop interventions that will > successfully reduce these errors and improve patient outcomes from > bloodstream infections. > > Trish Perl, M.D., s Hopkins University, Baltimore, land. > This study will examine whether the use of proper hand and > environmental cleaning agents will decrease the incidence of > Clostridium difficile colonization. > > Research into the public health aspects of West Nile Virus (WNV) in > the United States: > > B. Arciniegas, M.D., University of Colorado Health Sciences > Center, Denver, Colorado. The investigator will conduct a > prospective study of the neuropsychiatric manifestations of WNV to > help clarify the clinical presentation of this condition and to > guide future investigations in the diagnosis, treatment, and neuro- > rehabilitation of persons with this condition. > > C. Brault, Ph.D., the University of California , , > California. This work will generate fundamental data on the basis of > replication in the avian reservoir and insect vector of WNV to fill > gaps in knowledge of transmission and to improve existing > surveillance strategies. > > Margo A. Brinton, Ph.D., Georgia State University Research > Foundation, Inc. The investigators will study genetic polymorphisms > that confer West Nile Virus resistance in humans, and horses with > either asymptomatic or overt WNV disease. > > P. Busch, M.D., Blood Systems Inc., Blood Systems Research > Institute. This study proposes to utilize blood banks to identify > asymptomatic individuals with the virus and to track the natural > history of WNV infection with clinical, virologic and immunologic > markers to provide additional information on the epidemiology and > dynamics of WNV infection and risk assessment parameters. > > Wayne A. Rowley, Ph.D., Iowa State University. This study will > address the possibility that cottontail rabbits may play a role in > the ecology of WNV and serve as a potential source of WNV for > mosquitoes. > > R. Unnasch, Ph.D., University of Alabama at Birmingham, > Birmingham, AL. The study will focus on the epidemiology and > transmission of WNV in urban areas of the southeastern United States > to increase understanding of the ecology of WNV transmission. > > Organ Transplant Infection and Detection and Prevention Program: > > G. Pappas, M.D., University of Alabama at Birmingham, > Birmingham, Alabama. The investigators will improve surveillance of > invasive fungal infections in transplant patients in order to make > recommendations for prevention of these infections. > > L. Paterson, M.D., University of Pittsburgh, Pittsburgh, > Pennsylvania. This study will explore the epidemiology of fungal > infections in transplant recipients in order to develop strategies > for prevention of such infections. > > http://www.usnewswire.com/ > > -0- > > /© 2004 U.S. Newswire 202-347-2770/ Quote Link to comment Share on other sites More sharing options...
Guest guest Posted November 12, 2004 Report Share Posted November 12, 2004 Dang. Nobody threw their hat in the ring for Mycotic Diseases? OTOH, why study disorders that are not acknowledged to exist? --- In , " tigerpaw2c " <tigerpaw2C@n...> wrote: > > CDC Announces $5 Million in New Awards to Fight Emerging Infectious > Diseases > > 11/10/2004 3:12:00 PM > > http://releases.usnewswire.com/GetRelease.asp?id=39623 > --------------------------------------------------------------------- > ----------- > > State Desk, Health Reporter > > Contact: Morcone of the Centers for Disease Control and > Prevention, 404-639-1690 > > ATLANTA, Nov. 10 /U.S. Newswire/ -- The Centers for Disease Control > and Prevention today announced $5 million in new grants to support > infectious disease research in five major areas including influenza > vaccine effectiveness, antimicrobial resistance, Clostridium > difficile-associated diarrheal disease, West Nile virus infection, > and organ transplant-associated infections. > > " The primary objective of CDC's peer-reviewed research grants is to > support high quality studies whose findings can be applied by public > health practitioners and policy makers to improve health, " said Dr. > M. , director of CDC's National Center for Infectious > Diseases. " Each study aims to address an important public health > concern with substantial potential disease impact. " > > Listed below are brief descriptions of the studies, along with the > names of the principal investigators and their institutions. > > Annual influenza vaccine effectiveness: > > A. Belongia, M.D., Marshfield Clinic Research Foundation, > Marshfield, Wisconsin. This project aims to provide a rapid analysis > of influenza vaccine effectiveness throughout influenza season to > better understand how vaccination protects those who receive > vaccine. > > Applied research on antimicrobial resistance: > > Engemann, M.D., Duke University, Durham, North Carolina. The > investigators will study the impact of methicillin-resistant > Staphylococcus aureus on length of hospitalization and cost of > treatment. > > Ruth Lynfield, M.D., Minnesota Department of Health, Minneapolis, > Minnesota. This work will determine the economic costs of > methicillin-resistant S. aureus infections. > > J. Fraser, M.D., Washington University, St. Louis, > Missouri. This research will measure the economic costs of > infections caused by several antibiotic-resistant pathogens in a > hospital setting. > > R. , M.D., University of Minnesota, Minneapolis, > Minnesota. This study will address the transmission of antibiotic- > resistant E. coli organisms from poultry to humans. > > E. Wittum, Ph.D., Ohio State University Research Foundation, > Columbus, Ohio. The goal of this research is to assess the public > health risk of the antibiotic drug ceftiofur's use in food chain > animals. > > Prevention epicenters: Studies within this program are designed to > develop, implement, and evaluate the effectiveness of > epidemiologically-based strategies to improve healthcare quality and > ensure patient safety by preventing healthcare-associated infections > and reducing antimicrobial resistance. > > Fraser, M.D., Washington University, St. Louis, Missouri. > This research will examine the effect of antimicrobial agents on the > incidence of Clostridium difficile associated diahrrheal disease, > its impact on the cost of healthcare, and the influence that the use > of different disinfection agents have on its incidence. > > Loreen Herwaldt, M.D., University of Iowa, Iowa City, Iowa. This > group will analyze errors that resulted in incorrect identification > of infectious disease agents from blood cultures from laboratories > in several states in order to develop interventions that will > successfully reduce these errors and improve patient outcomes from > bloodstream infections. > > Trish Perl, M.D., s Hopkins University, Baltimore, land. > This study will examine whether the use of proper hand and > environmental cleaning agents will decrease the incidence of > Clostridium difficile colonization. > > Research into the public health aspects of West Nile Virus (WNV) in > the United States: > > B. Arciniegas, M.D., University of Colorado Health Sciences > Center, Denver, Colorado. The investigator will conduct a > prospective study of the neuropsychiatric manifestations of WNV to > help clarify the clinical presentation of this condition and to > guide future investigations in the diagnosis, treatment, and neuro- > rehabilitation of persons with this condition. > > C. Brault, Ph.D., the University of California , , > California. This work will generate fundamental data on the basis of > replication in the avian reservoir and insect vector of WNV to fill > gaps in knowledge of transmission and to improve existing > surveillance strategies. > > Margo A. Brinton, Ph.D., Georgia State University Research > Foundation, Inc. The investigators will study genetic polymorphisms > that confer West Nile Virus resistance in humans, and horses with > either asymptomatic or overt WNV disease. > > P. Busch, M.D., Blood Systems Inc., Blood Systems Research > Institute. This study proposes to utilize blood banks to identify > asymptomatic individuals with the virus and to track the natural > history of WNV infection with clinical, virologic and immunologic > markers to provide additional information on the epidemiology and > dynamics of WNV infection and risk assessment parameters. > > Wayne A. Rowley, Ph.D., Iowa State University. This study will > address the possibility that cottontail rabbits may play a role in > the ecology of WNV and serve as a potential source of WNV for > mosquitoes. > > R. Unnasch, Ph.D., University of Alabama at Birmingham, > Birmingham, AL. The study will focus on the epidemiology and > transmission of WNV in urban areas of the southeastern United States > to increase understanding of the ecology of WNV transmission. > > Organ Transplant Infection and Detection and Prevention Program: > > G. Pappas, M.D., University of Alabama at Birmingham, > Birmingham, Alabama. The investigators will improve surveillance of > invasive fungal infections in transplant patients in order to make > recommendations for prevention of these infections. > > L. Paterson, M.D., University of Pittsburgh, Pittsburgh, > Pennsylvania. This study will explore the epidemiology of fungal > infections in transplant recipients in order to develop strategies > for prevention of such infections. > > http://www.usnewswire.com/ > > -0- > > /© 2004 U.S. Newswire 202-347-2770/ Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.